EBOLA MCQ high yeild...

Discussion in 'PG Entrance Message Board' started by samuel, Oct 25, 2014.

  1. samuel

    samuel New Member

    QS on Ebola expected .Lets gather n ans few,
    1.Ebola virus formerly called
    a,congo virus
    b.zaire virus
    c.ziombe virus
    d,Marbung virus
    Dr Giri likes this.
  2. samuel

    samuel New Member

    Ebola virus is
    1,dsRNA
    2.ssRNA
    3.ds DNA
    4.ssDNA
  3. samuel

    samuel New Member

    in which family ebola virus belongs .?
    Group: Group V ((-)ssRNA)
    Order: Mononegavirales
    Family: Filoviridae
    Genus: Ebolavirus
    Species: Zaire ebolavirus
  4. samuel

    samuel New Member

    source , vector and mode of transmission .?

    The natural reservoir of Ebola virus is believed to be bats, particularly fruit bats, and it is primarily transmitted between
    humans and from animals to
    humans through body fluids.
  5. samuel

    samuel New Member

    •Group: Group V ((-)ssRNA)
    Order: Mononegavirales
    Family: Filoviridae
    Genus: Ebolavirus (discovered in 1976 by PETER PIOT)
    Species: Zaire ebolavirus(2014 outbreak); formerly called zaire virus. zaire is currently democratic republic of congo.
    5 species: zaire,sudan,bundibugyo,cote dlvoire, reston(mildest strain).
    the first 3 cause lethal d/s in humans.Reston not pathogenic to humans.
    The prototype Ebola virus, variant Mayinga (EBOV/May), was named for Mayinga N'Seka, a nurse who died during the 1976 Zaire outbreak.
    •The EBOV genome is a single-stranded RNA approximately 19,000 nucleotides long. It encodes seven structural proteins: nucleoprotein (NP), polymerase cofactor (VP35), (VP40), GP, transcription activator (VP30), VP24, and RNA polymerase (L).
    •IP=2-21 days,quarantine period of ebola virus suspect =21 days
    Concept of disease free period double of quarantine period 2x21 =42 days
    •On August 8, the WHO Director-General declared this outbreak a Public Health Emergency of International Concern.
    Case fatality rate 70% in current outbreak.
    •800 - 1000 nm in length,80 nm, pleomorphic. microscopy: bowl of spaghetti appearance.
    •Natural reservoir -unknown
    • Host (?)-Fruit bats of pteropodidae family
    Transmission to humans due to contact of body fluids
    •Signs and symptoms -sudden onset of fever,intense weakness, myalgia, headache,black vomiting ,diarrhea ,Maculopapular rash ,internal and external bleeding ,sore throat,chest pain,confusion
    •Late manifestations-Myalgias,Asymmetric and migratory arthralgias, Headache,Fatigue,Bulimia,Amenorrhea,Hearing loss,Tinnitus,U/l orchitis, Suppurative parotitis
    • Diagnosis-
    Low platelet count,Decreased wbc,Elevated ALT and AST,Prolonged prothrombin,partial thromboplatin and BT.
    antibody-capture enzyme-linked immunosorbent assay (ELISA),antigen-capture detection tests,serum neutralization test,reverse transcriptase polymerase chain reaction (RT-PCR) assay,electron microscopy,virus isolation by cell culture.
    •Supportive therapy with attention to intravascular volume, electrolytes, nutrition, and comfort care is of benefit to the patient. Intravascular volume repletion is one of the most important supportive measures.
    •Drugs (under research):
    Brincidofovir
    Favipiravir-triggers mutagenesis,so virus selfdestructs.
    FGI-106
    Lamivudine
    TKM-Ebola
    ZMapp(a blend of 3 monoclonal ab), BCX4430, JK-05
    List of known Ebola drugs in development. Most of these drugs try to block the duplication of the virus at the RNA polymerase level.
    •Cause of death- multiorgan failure.
    •Survivors can produce infectious virions for prolonged periods. Therefore, strict barrier isolation in a private room away from traffic patterns must be maintained throughout the illness. Patient’s urine, stool, sputum, and blood, along with any objects that have come in contact with the patient or the patient’s body fluids (such as laboratory equipment), should be disinfected with a 0.5% sodium hypochlorite solution. Patients who have died of Ebola virus disease should be buried promptly and with as little contact as possible.
    •Neutralising antibodies cannot be formed against Ebola in vivo because of high glucose content in its outer layer.
    •There are currently no licensed Ebola vaccines but 2 potential candidates are undergoing evaluation.Phase I clinical trials involve the administration of the vaccine to healthy human subjects to evaluate the immune response, identify any side effects and determine the appropriate dosage. As of October, 2014, such trials had begun for the replication-deficient cAd3-EBO Z vaccine,and for the replication-competent VSV-EBOV vaccine.
    •Ebola is a Category A Bioterrorism Agent and a Risk Group 4 Pathogen (requiring Biosafety Level 4-equivalent containment).
  6. samuel

    samuel New Member

    5 Species of EBOLA
    Bundibugyo ebolavirus
    Reston ebolavirus
    Sudan ebolavirus
    Taï Forest ebolavirus
    Zaire ebolavirus

Share This Page